Physician profile
Michael A Pickert
NPI 1275090300
$9,690.42
in general payments reported to CMS, 2019-2025
24 companies · $2,643 in 2025
The $2,643 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,871 · 2022: $808 · 2023: $3,230 · 2024: $1,139 · 2025: $2,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,212 · Consulting Fee: $1,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,211.50 |
| Consulting Fee | $1,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,082.22 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $1,978.80 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,064.83 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $799.70 | 2021-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $600.00 | 2023 | Mayzent |
| Otsuka America Pharmaceutical, INC. | $540.45 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $534.66 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $468.53 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $312.33 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $238.33 | 2021-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $206.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $175.14 | 2021-2025 | Fanapt |
| Daiichi Sankyo INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.08 | 2021-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $119.39 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $36.68 | 2021-2024 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $31.61 | 2021 | |
| Corium, LLC | $26.02 | 2025 | Azstarys |
| Gilead Sciences, INC. | $24.30 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.92 | 2022 | |
| Tris Pharma INC | $20.62 | 2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $18.10 | 2021 | |
| Neos Therapeutics, LP | $17.61 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pickert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.